Letter: Absence of chloroquine-induced ototoxicity in a fetus

Jb, Ross; Garatsos, Sotiros

doi:10.1001/archderm.109.4.573b

Cited by 12 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,18,19 Moreover, as also identi ed herein, there have been no reports of congenital malformations in children exposed to antimalarials used in SLE and rheumatoid arthritis patients. [31][32][33] Reinforcing these ndings, a recent study survey revealed that the majority of rheumatologists now continue to use antimalarials during lupus pregnancy and lactation. 34 Concerning antimalarial ototoxicity in rheumatic diseases, there is evidence for sensorineural deafness associated with chloroquine 35,36 and also with hydroxychloroquine treatment in patients with SLE and rheumatoid arthritis.…”

Section: Discussionmentioning

confidence: 99%

Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry

Borba

Turrini-Filho

Kuruma

et al. 2004

Lupus

View full text Add to dashboard Cite

The objective of this study was to assess child chloroquine ototoxicity after its use during the gestational period in systemic lupus erythematosus (SLE). Nineteen children over four years old were evaluated: nine were exposed to chloroquine diphosphate (CDP) during gestation and 10 were born from mothers that did not take this drug before conception or anytime during pregnancy (CONTROL). Pure tone audiometry was performed in all children and high and low frequency threshold means were compared to evaluate the hearing status. All nine mothers taking CDP were exposed to this drug at least during the first trimester of pregnancy (56% during the whole gestational period) and the mean time of CDP use was 6.1 +/- 2.9 months. No significant difference was found in children of CDP and CONTROL groups regarding age (7.6 +/- 4.4 versus 12.3 +/- 7.2 years; P = 0.10, respectively) and gender (P = 0.65). Pure tone high frequency thresholds, which are the first to be affected by ototoxic drugs, presented within normal limits in children exposed or not to CDP (8.5 +/- 5.0 versus 7.4 +/- 3.6 dBHL; P = 0.55, respectively). Likewise, the mean hearing thresholds at low frequencies were also similar in both groups (11.4 +/- 4.5 versus 11.9 +/- 3.0 dBHL; P = 0.66). In conclusion, child in utero exposure to chloroquine diphosphate does not seem to induce hearing impairment as measured by pure tone audiometry, reinforcing its safe use during pregnancy of lupus patients.

show abstract